The FirstTake Podcast – More questions than answers for Sage and Biogen
Update: 2022-02-17
Description
FirstWord Pharma PLUS editors Virginia Li and Simon King discuss Phase III clinical data for a new depression therapy being co-developed by Sage Therapeutics and Biogen, the FDA’s new - but also old – commissioner, Robert Califf, whose reappointment five years after he first held the role was confirmed by the US senate this week and whether Regeneron can make its multi-billion dollar eye-disorder therapy Eylea an even more compelling product for physicians.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
